Health Care • Biotechnology: Pharmaceutical Preparations
$82.70 ▲ +0.39
(+0.47%)
MKT CAP: $4.63B • VOL: 849.1K
52W L $32 52W H $118
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$69
MEDIAN
$93
MEAN
$94
HIGH
$112
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DNTH TAPE
DNTH // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $100.07 | $95.10 | 2025-02-14 | $75.26 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $104.20 | $97.59 | 2025-02-06 | $77.74 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $94.28 | $90.97 | 2025-01-29 | $79.39 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $84.35 | — | 2025-01-17 | $81.05 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $72.78 | $78.56 | 2025-01-09 | $73.60 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $98.41 | $86.01 | 2024-12-18 | $71.95 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $80.22 | $83.53 | 2024-12-04 | $76.91 | -4.3% | 48% | C |